New drug shows promise in battle against rare blood cancer
NCT ID NCT07033598
First seen Feb 05, 2026 · Last updated May 10, 2026 · Updated 14 times
Summary
This study compares a new drug, pacritinib, to the standard drug hydroxyurea for adults with advanced chronic myelomonocytic leukemia (CMML). The goal is to see if pacritinib controls the disease better and causes fewer side effects. Participants will be randomly assigned to take either pacritinib or hydroxyurea for up to 48 weeks and will be followed for one year after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOMONOCYTIC, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Email: •••••@•••••
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Email: •••••@•••••
Contact
-
Winship Cancer Institute at Emory
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.